Loading...
The molecular targets of approved treatments for pulmonary arterial hypertension
Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an addition...
Na minha lista:
| Udgivet i: | Thorax |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4717417/ https://ncbi.nlm.nih.gov/pubmed/26219978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2015-207170 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|